APLS:NGS-Apellis Pharmaceuticals Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 18.88

Change

0.00 (0.00)%

Market Cap

USD 1.19B

Volume

0.18M

Average Target Price

USD 34.00 (+80.08%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-04-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
SHPG Shire plc

N/A

USD 54.84B
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD 42.99B
REGN Regeneron Pharmaceuticals Inc.

N/A

USD 36.43B
ALXN Alexion Pharmaceuticals Inc.

N/A

USD 28.26B
INCY Incyte Corporation

N/A

USD 15.85B
BMRN BioMarin Pharmaceutical Inc.

N/A

USD 14.83B
BIVV Bioverativ Inc.

N/A

USD 11.36B
SGEN Seattle Genetics Inc.

N/A

USD 11.13B
KITE Kite Pharma Inc.

N/A

USD 10.31B
IONS Ionis Pharmaceuticals Inc.

N/A

USD 10.10B

ETFs Containing APLS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 43.14% 75% C 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.14% 75% C 86% B
Trailing 12 Months  
Capital Gain -23.00% 53% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.00% 53% F 27% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -3.12% 42% F 27% F
Dividend Return -3.12% 42% F 24% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.95% 95% A 83% B
Risk Adjusted Return -26.14% 35% F 20% F
Market Capitalization 1.19B 84% B 73% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -8.10 77% C+ 80% B-
Price/Book Ratio 5.43 26% F 20% F
Price / Cash Flow Ratio -2.09 69% D+ 83% B
Price/Free Cash Flow Ratio -7.93 66% D 78% C+
Management Effectiveness  
Return on Equity -71.28% 44% F 15% F
Return on Invested Capital -62.31% 45% F 17% F
Return on Assets -58.44% 37% F 11% F
Debt to Equity Ratio 16.00% 44% F 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.